Dear all,

welcome to the next MET Seminar on Thu 31.10. at 13.00 in Arvo F115. The speaker is Dr. Kristian W. Pajtler from the Hopp-Children’s Cancer Center Heidelberg (KiTZ), Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

The title of his talk is:

Next generation diagnostics to tackle brain tumors

Dr. Kristian W. Pajtler is a well-known pediatrician who has done pioneering work with ependymomas, but also with other pediatric tumors. He is currently running INFORM project using deep sequencing to characterize pediatric tumors in relapsed patients who currently have no effective treatment available (https://www.dkfz.de/en/inform/index.html). Patients have also been treated with genomic knowledge and good responses to drug treatments have been found.

In addition, Dr. Pajtler is interested in the use of fluid biopsies, especially cell-free DNA, as part of clinical therapy and he is conducting research in this field.

Selected publications:

YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis.
Pajtler KW, Wei Y, Okonechnikov K, Silva PBG, Vouri M, et al.
Nat Commun. 2019 Sep 2;10(1):3914. doi: 10.1038/s41467-019-11884-5.

MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, et al.  
Acta Neuropathol. 2019 Aug 14. doi: 10.1007/s00401-019-02056-2.

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW, Wen J, Sill M, Lin T, Orisme W, et al. Acta Neuropathol. 2018 Aug;136(2):211-226. doi: 10.1007/s00401-018-1877-0. Epub 2018 Jun 16.

Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, et al. Nature. 2018 Jan 4;553(7686):101-105. doi: 10.1038/nature25169. Epub 2017 Dec 20.

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, et al.
Cancer Cell. 2015 May 11;27(5):728-43. doi: 10.1016/j.ccell.2015.04.002.

Coffee and snacks before the seminar!